Supplementary Table Legends 1-2, Figure Legends 1-6 from Hedgehog-Producing Cancer Cells Respond to and Require Autocrine Hedgehog Activity

Singh, Samer; Wang, Zhiqiang; Liang Fei, Dennis; Black, Kendall E.; Goetz, John A.; Tokhunts, Robert; Giambelli, Camilla; Rodriguez-Blanco, Jezabel; Long, Jun; Lee, Ethan; Briegel, Karoline J.; Bejarano, Pablo A.; Dmitrovsky, Ethan; Capobianco, Anthony J.; Robbins, David J.

doi:10.1158/0008-5472.22388919.v1

00085472can102313-sup-tl1-2_fl_1-6.pdf (87.03 kB)

Supplementary Table Legends 1-2, Figure Legends 1-6 from Hedgehog-Producing Cancer Cells Respond to and Require Autocrine Hedgehog Activity

journal contribution

posted on 2023-03-30, 20:29 authored by Samer Singh, Zhiqiang Wang, Dennis Liang Fei, Kendall E. Black, John A. Goetz, Robert Tokhunts, Camilla Giambelli, Jezabel Rodriguez-Blanco, Jun Long, Ethan Lee, Karoline J. Briegel, Pablo A. Bejarano, Ethan Dmitrovsky, Anthony J. Capobianco, David J. Robbins

Supplementary Table Legends 1-2, Figure Legends 1-6 from Hedgehog-Producing Cancer Cells Respond to and Require Autocrine Hedgehog Activity

History

ARTICLE ABSTRACT

A number of Smoothened (SMO) pathway antagonists are currently undergoing clinical trials as anticancer agents. These drugs are proposed to attenuate tumor growth solely through inhibition of Hedgehog (HH), which is produced in tumor cells but acts on tumor stromal cells. The pivotal argument underlying this model is that the growth-inhibitory properties of SMO antagonists on HH-producing cancer cells are due to their off-target effects. Here, we show that the tumorigenic properties of such lung cancer cells depend on their intrinsic level of HH activity. Notably, reducing HH signaling in these tumor cells decreases HH target gene expression. Taken together, these results question the dogma that autocrine HH signaling plays no role in HH-dependent cancers, and does so without using SMO antagonists. Cancer Res; 71(13); 4454–63. ©2011 AACR.